- Global Pharma News & Resources

uBiome Appoints Dr. Hannah Holscher, PhD, RD, Director of the Nutrition & Human Microbiome Lab at University of Illinois, to its Scientific Advisory Board

uBiome Appoints Dr. Hannah Holscher, PhD, RD, Director of the Nutrition & Human Microbiome Lab at University of Illinois, to its Scientific Advisory Board The leader in microbial genomics appoints clinical nutritionist and gut microbiome researcher to its board of scientific advisors.

PR Newswire

SAN FRANCISCO, Nov. 30, 2018

SAN FRANCISCO, Nov. 30, 2018 /PRNewswire-PRWeb/ -- uBiome, the leader in microbial genomics, announces the addition of Dr. Holscher, PhD, RD, Director of the Nutrition and the Human Microbiome Laboratory and Assistant Professor of Nutrition at University of Illinois at Urbana-Champaign, to its Scientific Advisory Board. Joining the board of leading scientists and doctors from around the world, Dr. Holscher will bring to uBiome extensive insight on the impact of nutrition on the human gut microbiome. The appointment will help uBiome continue its advancement in human microbiome research.

"Dr. Holscher's goal of improving human health through increased understanding of the microbiome aligns with uBiome's mission," Dr. Jessica Richman, PhD, co-founder and CEO of uBiome, said. "We are thrilled to welcome her to our advisory board and look forward to drawing on her extensive knowledge."

Dr. Holscher is an assistant professor of nutrition in the Department of Food Science and Human Nutrition. She also has faculty appointments in the Division of Nutritional Sciences, the Institute of Genomic Biology, and the National Center for Supercomputing Applications. As the Director of the Nutrition and Human Microbiome Laboratory, her research aims to enhance human health through dietary modulation of the gut microbiome with a special focus on the link between diet, gut microbiome, and health and disease. Dr. Holscher was recognized as a New Innovator in Food and Agriculture Research (2017), has received funding from the United States Department of Agriculture and the Foundation for Food and Agriculture Research, and is the chair of the Nutrition Translation Research Interest Section of the American Society for Nutrition.

About joining uBiome's Scientific Advisory Board, Dr. Holscher said, "I am looking forward to working with uBiome. We have a common research goal, to advance microbiome research to improve human health, which should help make for a positive working relationship."

In addition to Dr. Holscher, the uBiome Scientific Advisory Board also includes Dr. Joseph DeRisi (MacArthur Genius and UCSF professor), Dr. Atul Butte (head of the Institute for Computational Health Sciences at UCSF), Dr. Katherine Pollard (Director, Gladstone Institute for Data Science and Biotechnology), Dr. Joel Palefsky (UCSF School of Medicine professor), Dr. George Church (leading geneticist at Harvard University), Dr. Liz Lipski (Academic Director of Nutrition and Integrative Health Programs at Maryland University of Integrative Health), Dr. Elaine Hsiao, PhD (UCLA), and other leading scientists. The company's Medical Advisory Board includes Dr. Alan Green (Society for Participatory Medicine), Dr. Leo Treyzon (Cedars-Sinai Medical Center), Dr. Cynthia Geyer (Medical Director of Canyon Ranch, Lenox), Dr. Robynne Chutkan (Georgetown University Hospital), Michael Docktor (Boston Children's Hospital), Dr. Tiffany Lester (Medical Director of Parsley Health in San Francisco), Dr. Joel Kahn (Founder of of the Kahn Center for Cardiac Longevity), as well as other accomplished clinicians.

About uBiome
Founded in 2012, uBiome is the leader in microbial genomics. The Company's mission is to advance the science of the microbiome and make it useful to people. uBiome combines its patented proprietary precision sequencing™ with machine learning and artificial intelligence to develop wellness products, clinical tests, and therapeutic targets. uBiome has filed for over 250 patents on its technology, which includes sample preparation, computational analysis, molecular techniques, as well as diagnostic and therapeutic applications.

uBiome's commercial products include SmartGut™, the world's first sequencing-based clinical microbiome test, which identifies microbes in the gut for patients with chronic gut conditions such as IBD, IBS, Crohn's Disease, and ulcerative colitis; SmartJane™, the first sequencing-based women's health screening test, which genotypes all 19 clinically relevant strains of HPV, identifies four common STDs, and surveys more than 20 vaginal microbes associated with bacterial vaginosis and other conditions; and Explorer™, a health and wellness product to understand the role that food and lifestyle can play in wellness.

uBiome's platform has been used by hundreds of thousands of consumers, patients, and doctors and more than 200 research institutions around the world, including the US Centers for Disease Control (CDC), US National Institutes of Health (NIH), Harvard University, Stanford University, the Massachusetts Institute of Technology (MIT), University of California, San Francisco, Oxford University, and the University of Sydney.

Since its launch, the company has received widespread recognition including CNN 10: Startups to Watch, the IVY Technology Award, CNN Future 30, and was named one of Fast Company's Most Innovative Companies in Healthcare in 2016 and in Data Science in 2018, as well as a Technology Pioneer from the World Economic Forum in 2018. For more information, visit



Editor Details

  • Company:
    • PR Newswire
  • Website:
Last Updated: 30-Nov-2018